Table 2.
Details of seven HBV‐DNA‐positive patients
| Interventions | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient No. | Age | Sex | Type of cancer | Regimen | Period until activation (months) | HBV‐DNA titer (peak) (log IU/mL) | NAA | CT discontinuation | Clinical course | Total DEX dose (mg) | DEX average dose per day (mg/day) |
| 1 | 63 | F | Gyne | PAC +CBDCA | 4 | <1.3 | − | No | Better | 140.4 | 1.5 |
| 2 | 72 | M | Resp | IRI +CDDP | 7 | <1.3 | − | Yes | Stable | 66 | 2.6 |
| 3 | 74 | M | Resp | BEV +PEM +CDDP | 6 | <1.3 | − | No | Stable | 159.9 | 2.9 |
| 4 | 76 | M | Gastr | Cape +L‐OHP | 12 | 1.4 | + | Yes | Better | 26.4 | 0.3 |
| 5 | 64 | M | Resp | ETP +CDDP | 1 | 1.4 | + | Yes | Better | 112.2 | 3.0 |
| 6 | 69 | F | Gyne | PAC +CBDCA | 0a | <1.3 | − | Yes | Better | 430.2 | 1.3 |
| 7 | 81 | M | Resp | GEM +CDDP | 3b | < 1.3 | − | No | Stable | 156.4 | 1.5 |
Abbreviations: BEV, bevacizumab; Cape, capecitabine; CBDCA, carboplatin; CDDP, cisplatin; CT, chemotherapy; DEX, dexamethasone; ETP, etoposide; Gastr, gastrointestinal; GEM, gemcitabine; Gyne, gynecological; IRI, irinotecan; L‐OHP, oxaliplatin; NAA, nucleic acid analogues; PAC, paclitaxel; PEM, pemetrexed; Resp, respiratory.
a
Positive for HBV‐DNA before chemotherapy.
b
No data on HBV‐DNA before chemotherapy.
In the clinical course, “Stable” and “Better” mean no changed and decreased HBV‐DNA levels, respectively. The average DEX dose per day was calculated as the total dexamethasone dose divided by the length of the chemotherapy duration in days.